Certara (NASDAQ:CERT) Releases FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.410-0.440 for the period, compared to the consensus earnings per share estimate of 0.410. The company issued revenue guidance of $380.0 million-$385.0 million, compared to the consensus revenue estimate of $386.2 million. Certara also updated its FY24 guidance to $0.41-0.44 EPS.

Analysts Set New Price Targets

Several research firms recently weighed in on CERT. Robert W. Baird dropped their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Finally, Barclays lowered their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $15.92.

Certara Price Performance

NASDAQ:CERT traded up $0.04 during midday trading on Friday, reaching $11.03. The stock had a trading volume of 1,081,810 shares, compared to its average volume of 1,148,975. Certara has a 1-year low of $9.99 and a 1-year high of $19.87. The firm’s fifty day simple moving average is $11.02 and its 200-day simple moving average is $13.70. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.06 EPS. As a group, research analysts anticipate that Certara will post 0.27 earnings per share for the current year.

Insider Activity at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.